Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Anjan K, Nayak"'
Autor:
Brahmam Pujala, Sreekanth A. Ramachandran, Mukesh Sonawane, Maruti M. Kamble, Dayanand Panpatil, Swati Adhikari, Sanjeev Soni, Venkata Subbareddy, Bharat U. Shinde, Anjan K. Nayak, Chandni Bansal, Ashu Gupta, Kakoli Mukherjee, Anil K. Agarwal, Javier Guerrero, Francisco J. Herrera, Sebastian Bernales, Mausumee Guha, Sarvajit Chakravarty, Son M. Pham, Roopa Rai
Publikováno v:
Bioorganicmedicinal chemistry letters. 75
Compound 1 is a potent TGF-β receptor type-1 (TGFβR1 or ALK5) inhibitor but is metabolically unstable. A solvent-exposed part of this molecule was used to analogue and modulate cell activity, liver microsome stability and mouse pharmacokinetics. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::284f050e012e992686c32f90ce8a56e0
https://pubmed.ncbi.nlm.nih.gov/36089110
https://pubmed.ncbi.nlm.nih.gov/36089110
Autor:
Jennifer, Alfaro, Felipe, Pérez de Arce, Sebastián, Belmar, Glenda, Fuentealba, Patricio, Avila, Gonzalo, Ureta, Camila, Flores, Claudia, Acuña, Luz, Delgado, Diana, Gaete, Brahmam, Pujala, Anup, Barde, Anjan K, Nayak, T V R, Upendra, Dhananjay, Patel, Shailender, Chauhan, Vijay K, Sharma, Stacy, Kanno, Ramona G, Almirez, David T, Hung, Sarvajit, Chakravarty, Roopa, Rai, Sebastián, Bernales, Kevin P, Quinn, Son M, Pham, Emma, McCullagh
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 361(2)
Although new targeted therapies, such as ibrutinib and idelalisib, have made a large impact on non-Hodgkin's lymphoma (NHL) patients, the disease is often fatal because patients are initially resistant to these targeted therapies, or because they eve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f7e8d9a06c49ef42e973fc8a84ac5ee2
https://pubmed.ncbi.nlm.nih.gov/28298527
https://pubmed.ncbi.nlm.nih.gov/28298527